Icon One

Treatment Paradigms. Shifted.

The ELIAS cancer immunotherapy (ECI ®) platform offers a completely new approach to cancer treatment. It is built upon 50+ years of intensive scientific and medical research into the interactions between cancer and the immune response. ECI utilizes a combination of cancer vaccination pretreatment and activated “killer” T cell immunotherapy


Two-step Treatment. Explained.

Cancer treatment with ECI involves the following sequential and dependent steps:

Step One
  1. Step One: Personalized vaccine stimulates a cancer-specific immune response.
  2. A. Cancer tissue is surgically removed by the veterinarian.
  3. B. This tissue is shipped to ELIAS Animal Health's manufacturing facility.
  4. C. A personalized vaccine is produced and sent back to the veterinarian.
  5. D. The vaccines are administered on a weekly or bi-weekly basis to stimulate the immune system T cells to recognize the dog's cancer.
Step Two
  1. Step Two: T Cell Harvest and Reinfusion.
  2. E. Two weeks following step one, the veterinary oncologist uses apheresis to harvest the population of cancer-specific T cells generated by the vaccination.
  3. F. These T cells are shipped to ELIAS for processing.
  4. G. A proprietary, patented process is used to produce an activated, blood-derived population of T cells functionally empowered and numerically expanded.
  5. H. This tumor-specific population of killer T cells is returned to the veterinarian for intravenous administration.

Harvesting Process. Demystified.

Apheresis is a medical technology in which the whole blood of the patient can be passed through a medical instrument that separates out a particular component, in this case T cells, so they can be removed for further processing.

Apheresis Video
Icon Two

ECI Protocol. Timelined.

Although every patient and every experience is unique, there is a basic timeframe for ECI treatment and evaluation. After the initial surgery to remove the cancer, a series of vaccinations will follow. After the vaccinations, the personalized T cells are collected and activated. Following intravenous infusion of activated ‘killer’ T cells, there may be several follow-up evaluations.

Step List

Therapeutic Potential. Amplified.

ECI is a promising oncology treatment modality for canine cancer for several reasons:

  • It delivers the potential for tumor-specific cytotoxicity.
  • Clinical outcomes of ELIAS' osteosarcoma trial, as reported at ACVIM in June, showed adverse events were mostly mild to moderate and were typically transient in nature.
  • This personalized approach could be useful for treating numerous types of cancer and may limit or avoid the use of chemotherapy and radiation.


Preliminary Study Results & History of Treatment Outcomes